Atopic Dermatitis Treatment Landscape

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Incidence of Atopic Dermatitis

Location, Location, Location

Assessing the Severity of AD Comparing EASI, SCORAD, and IGA

Patient-Reported Burden of AD

Impact of AD on Quality of Life

Impact of AD on Mental Health

Burden of AD

Novel Treatments for AD

CHRONOS: Dupilumab for the Management of Moderate-to-Severe AD

CHRONOS: Dupilumab Efficacy

Dupilumab Increased Incidence of Conjunctivitis

Lebrikizumab

Lebrikizumab Efficacy: Results From TREBLE

Tralokinumab Efficacy

Nemolizumab: IL-31R Targeting Antibody

Nemolizumab Efficacy

JAK Inhibitors

Novel Topical Agents: Crisaborole

Topical JAK Inhibitors

Other Agents in Development for AD

Is the Patient a Candidate for Systemic Treatment

Take-Home Messages

Abbreviations

Abbreviations (cont)